PUBLISHER: Grand View Research | PRODUCT CODE: 1750847
PUBLISHER: Grand View Research | PRODUCT CODE: 1750847
The global digital respiratory devices market size is expected to reach USD 304.28 billion by 2030, registering a CAGR of 28.92% from 2025 to 2030, based on a new report by Grand View Research, Inc. The market growth can be attributed to an increase in the number of people with chronic respiratory diseases (CRDs) such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, and lung disorders. Moreover, COVID-19 has prompted a rise in the number of innovative digital devices and systems for respiratory and pulmonary care, which is driving the demand for digital respiratory devices. For instance, in March 2022, Brisbane-based ResApp informed about the positive data that it received from the Covid-19 instant screening test. The coughing sound is used with the help of a smartphone to detect the presence of the COVID-19 virus in the new test.
Furthermore, during the COVID-19 outbreak, several patients were unable to receive consultations and treatments in person. The pandemic demonstrated how serious respiratory illnesses and infections may become if not treated quickly and carefully. As a result of this, in the post-pandemic era, smart inhaler adoption is anticipated to increase as healthcare professionals turn to connected medical devices to ensure that patients receive the best care and consultation possible, regardless of the circumstance.
Additionally, a growing number of technological advancements in the field of digital respiratory devices are scaling up the digital technologies into existing product portfolios to improve the efficiency of medication as well as the management of asthma and COPD. Moreover, recent studies conducted by research experts have shown that smart inhaler technology may be able to resolve this problem and offer patients a simple way to keep up treatment compliance and control symptoms. For example, a 2019 study from the Cleveland Clinic found that COPD patients utilizing Propeller smart inhalers had a significantly lower risk of being admitted to the hospital, with a nearly 35% drop in visits compared to the previous year (2020).